A U.S. appeals court on Tuesday revived a lawsuit against AstraZeneca Plc, Pfizer Inc and other companies over allegations their contracts with Iraq’s health ministry helped fund terrorism that killed Americans during the war in Iraq. The plaintiffs contend that the militia group Jaysh al-Mahdi, sponsored by the terrorist group Hezbollah, controlled Iraq’s health ministry…
US Court Revives Lawsuit Against Pfizer, Others on Iraq Terrorism Funding Claims
Biden Moves to Double the Government’s Order of New Pfizer COVID-19 Pill
President Joe Biden Tuesday directed the federal government to double its purchase of Pfizer’s oral antiviral treatment, Paxlovid. This addition increases the U.S. total purchase from Pfizer from 10 million to 20 million therapeutic courses of the new pill. The U.S. Food and Drug Administration (FDA) authorized the emergency use of Paxlovid last month for…
‘Commercial Interests Colliding With Public Health’ in COVID-19 Vaccine Industry: Researcher
January 2, 2022
admin
AstrazenecaAustraliaBusiness & EconomyBusinesses in COVID-19CCP VirusCompaniesCOVAX-19Expert ViewmRNAmRNA vaccineNikolai PetrovskyPfizerSpikogenTherapeutic Goods AdministrationVaccines & SafetyWorld
0 Comment
Billions of dollars in government funding ploughed into COVID-19 vaccine research during the pandemic has helped push the boundaries of drug research beyond their usual limits in the race to create the jab, says lead researcher of the Spikogen (or COVAX-19) vaccine. Professor Nikolai Petrovsky says the pandemic has been a springboard for major drug…
Pfizer’s Antiviral COVID-19 Pill Approved by Britain’s Health Regulators
Britain’s drugs regulator approved use authorization for Pfizer’s COVID-19 antiviral pill just about one month after it became the first country to approve a similar oral antiviral treatment produced by Merck & Co.’s. The Medicines and Healthcare Products Regulatory Agency (MHRA) said Pfizer’s pill, named Paxlovid, can be given to people aged 18 and older…
Young Men More Likely to Get Heart Inflammation After Pfizer’s Booster Than COVID-19: Study
Males under 40 years old are more likely to experience heart inflammation after getting a booster shot of Pfizer’s COVID-19 vaccine than COVID-19 itself, according to a recently published study. Males in the age group had a myocarditis incidence rate ratio of 7.6 in the 28 days following receipt of a Pfizer booster, researchers with…
COVID Antiviral Pills Cause Life-Threatening Reactions When Used With Many Common Meds: FDA
Pfizer’s antiviral oral drug developed to treat COVID-19 can cause severe or life-threatening effects when used with common medications including some anti-coagulants, some anti-depressants, and some cholesterol-lowering statins, according to the Food and Drug Administration (FDA) (pdf). FDA does not recommend Paxlovid for those with severe kidney or liver disease. The FDA on Dec. 22 granted emergency…
Israel Orders Thousands of Pfizer’s Oral COVID Treatment After Granting Emergency Use Approval
Israel’s Health Ministry on Sunday granted emergency approval to an anti-viral oral COVID-19 medication developed by pharmaceutical company Pfizer. Officials ordered roughly 100,000 doses of the pills in an effort to help combat a new coronavirus wave brought about by the fast-spreading Omicron variant. The doses are expected to arrive in the country by Wednesday at the earliest, Hebrew-language Channel…
COVID-19 Vaccination Bookings Open for Australian Kids Aged 5 to 11
Parents across Australia are now able to book COVID-19 vaccinations for their children aged 5 to 11. Bookings opened from Dec. 15, with inoculations for this age group set to commence on Jan.10 through state and territory-run clinics, pharmacies, Aboriginal Community Controlled Health Services, and Commonwealth Vaccination Centres. Children aged 5 to 11 will receive two…
How Much Revenue Could Pfizer’s Oral COVID-19 Pill Fetch?
Pfizer Inc. announced Wednesday its oral COVID-19 antiviral pill, Paxlovid, has been authorized for use by the U.S. Food and Drug Administration. Pfizer Analysts SVB Leerink analyst Geoffrey Porges has a Market Perform rating and a $52 price target for Pfizer. BofA Securities analyst Geoff Meacham maintained a Neutral rating and a $59 price target. Broad Label, Increased…
Some Vaccinated Australian Seniors Remain Hesitant on Vaccine Safety
Among older Australians who have said they were overwhelmingly likely to get a COVID-19 vaccine, some are still raising concerns of vaccine safety and efficacy. COVID-19, the disease caused by the CCP (Chinese Communist Party) virus, has tragically led to the death of 2,168 Australians, 96 percent of whom were aged 50 and over. Currently,…
US News
RSS Error: A feed could not be found at `https://www.theepochtimes.com/c-us/feed`; the status code is `200` and content-type is `text/html; charset=utf-8`